BioScrip Inc. Hits New 52-Week Low at $7.91 (BIOS)
BioScrip (NASDAQ:BIOS)’s share price reached a new 52-week low during trading on Thursday, StockRatingsNetwork.com reports. The stock traded as low as $7.91 and last traded at $7.96, with a volume of 511,216 shares traded. The stock had previously closed at $8.02.
A number of analysts have recently weighed in on BIOS shares. Analysts at Jefferies Group cut their price target on shares of BioScrip from $17.00 to $11.00 in a research note to investors on Friday, September 27th. They now have a “buy” rating on the stock. Separately, analysts at Noble Financial cut their price target on shares of BioScrip from $16.00 to $13.00 in a research note to investors on Thursday, September 26th. They now have a “buy” rating on the stock. Finally, analysts at Zacks reiterated a “hold” rating on shares of BioScrip in a research note to investors on Wednesday, September 25th. They now have a $15.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $13.75.
BioScrip has a 1-year low of $8.40 and a 1-year high of $17.62. The stock has a 50-day moving average of $13.43 and a 200-day moving average of $13.84. The company’s market cap is $539.5 million.
BioScrip (NASDAQ:BIOS) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.09. The company had revenue of $190.73 million for the quarter, compared to the consensus estimate of $206.47 million. During the same quarter in the previous year, the company posted ($0.07) earnings per share. The company’s revenue for the quarter was up 22.3% on a year-over-year basis. On average, analysts predict that BioScrip will post $0.20 earnings per share for the current fiscal year.
BioScrip, Inc (NASDAQ:BIOS) is a provider of pharmacy and home health services, which partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and the delivery of prescription medications and home health services.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.